NCT03663218 2026-03-18
PREPARE SBRT
Weill Medical College of Cornell University
Phase NA Active not recruiting
Clinical Trials
886 trialsNCT04902040 2026-03-18
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT03274687 2026-03-16
Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer
NRG Oncology
Phase 3 Completed
NCT04037254 2026-03-16
Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring
NRG Oncology
Phase 1/2 Completed
NCT01804712 2026-03-12
Rituximab Neoadjuvant Therapy in Patients With Prostate Cancer Scheduled to Undergo Radical Prostatectomy
University of California, San Diego
Phase EARLY_PHASE1 Completed
NCT03239145 2026-03-12
Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Dana-Farber Cancer Institute
Phase 1 Completed
NCT03778112 2026-03-09
MRI Guided SBRT for Localized Prostate Cancer
Rush University Medical Center
Phase NA Active not recruiting
NCT03808077 2026-03-09
The Effect of Deep Versus Moderate Muscle Relaxants in Men During and After Robotic Surgery for Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT01616875 2026-03-06
Bristol Bladder Trial
University Hospitals Bristol and Weston NHS Foundation Trust
Phase 2 Completed
NCT05764005 2026-03-06
Optimizing Active Surveillance in Low-Risk Prostate Cancer: a Pilot Study
University of Michigan Rogel Cancer Center
Phase NA Completed
NCT02946996 2026-03-05
Study of Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients Receiving Androgen Deprivation Therapy
Medical University of South Carolina
Phase 2 Terminated
NCT04288687 2026-03-04
A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT01885949 2026-02-24
Tivozanib + Enzalutamide in Adv Prostate Cancer
Massachusetts General Hospital
Phase 2 Terminated
NCT02522715 2026-02-24
Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer
OHSU Knight Cancer Institute
Phase 1/2 Active not recruiting
NCT03254420 2026-02-20
RCMIGI
Institut du Cancer de Montpellier - Val d'Aurelle
Phase NA Active not recruiting
NCT04461509 2026-02-20
High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy
Cedars-Sinai Medical Center
Phase 2 Completed
NCT04751929 2026-02-20
Abemaciclib With or Without Atezolizumab for mCRPC
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT00809991 2026-02-18
Hypofractionated Adaptive Image-Guided Radiation Therapy for Localized Adenocarcinoma of the Prostate
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT02274779 2026-02-13
OLIGOPELVIS
Institut Cancerologie de l'Ouest
Phase 2 Completed
NCT05320406 2026-02-12
REVELUTION
Emory University
Phase 2 Active not recruiting
NCT01517451 2026-02-11
Radiation and Androgen Ablation for Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT02964078 2026-02-10
Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT03203473 2026-02-06
Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT05366842 2026-01-30
Patient-Reported Erectile Recovery and Quality of Life Outcomes With Lyopreserved Placental Tissue Applied Directly Over Neurovascular Bundle During Nerve Sparing Radical Prostatectomy Versus Standard of Care
Johns Hopkins University
Phase 2 Terminated
NCT03474497 2026-01-29
UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
University of California, Davis
Phase 1/2 Active not recruiting
NCT03553602 2026-01-29
BEACON
Loyola University
Phase 1/2 Terminated
NCT04856189 2026-01-29
Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma
University of California, Davis
Phase 1/2 Terminated
NCT02690558 2026-01-28
Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy
UNC Lineberger Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT03796767 2026-01-28
SOAR
University of Utah
Phase 2 Active not recruiting
NCT04018053 2026-01-27
18Fluorine-Fluciclovine PET/CT for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy
Brigham and Women's Hospital
Phase EARLY_PHASE1 Active not recruiting
NCT03565835 2026-01-26
Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer
Montefiore Medical Center
Phase 2 Completed
NCT03246347 2026-01-23
A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer
Wake Forest University Health Sciences
Phase 2 Active not recruiting
NCT03503344 2026-01-21
PILLAR
University of California, San Francisco
Phase 2 Completed
NCT04377932 2026-01-21
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Baylor College of Medicine
Phase 1 Active not recruiting
NCT05470036 2026-01-16
IMPRINT
University of California, San Diego
Phase NA Completed
NCT01810757 2026-01-15
HYBRID
Institute of Cancer Research, United Kingdom
Phase NA Completed
NCT03556904 2026-01-15
FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT04763824 2026-01-14
KANSURVIVE
University of Kansas Medical Center
Phase NA Completed
NCT04870515 2026-01-09
Diet and Physical Activity Intervention for the Prevention of ADT-Induced Metabolic Changes in Patients With Prostate Cancer, TRIPLE-A PILOT Study
Fred Hutchinson Cancer Center
Phase NA Completed
NCT03996005 2026-01-08
MRI-TULSAP
University Hospital, Strasbourg, France
Phase NA Completed
NCT04897763 2026-01-07
PERTINENCE
Institut Cancerologie de l'Ouest
Phase EARLY_PHASE1 Completed
NCT04022343 2026-01-05
Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer
Emory University
Phase 2 Active not recruiting
NCT06016725 2026-01-02
E-PROOF
Ohio State University Comprehensive Cancer Center
Phase NA Completed
NCT03809000 2025-12-30
STEEL
RTOG Foundation, Inc.
Phase 2 Active not recruiting
NCT04831138 2025-12-19
Non-Contrast Perfusion Using Arterial Spin Labeled MR Imaging for Assessment of Therapy Response in Metastatic Renal Cell Carcinoma
University of Texas Southwestern Medical Center
Phase NA Terminated
NCT05470699 2025-12-17
RefleXion PET/CT Imaging Performance in Patients With Prostate Cancer
City of Hope Medical Center
Phase NA Active not recruiting
NCT02772562 2025-12-12
Adjuvant PROSTVAC-V/F in Subjects at High Risk for Relapse After Radical Prostatectomy
Medical University of South Carolina
Phase 2 Terminated
NCT04176497 2025-12-11
PSMA-PET/MRI Unfavorable-Risk Target Volume Pilot Study
UNC Lineberger Comprehensive Cancer Center
Phase 2 Terminated
NCT04905082 2025-12-11
HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics
City of Hope Medical Center
Phase NA Active not recruiting
NCT03260504 2025-12-08
Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer
University of Washington
Phase 1 Terminated